Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer is a paper indexed in PICO Portal from OpenAlex.
How many citations does Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer have?
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer has 261 citations in the OpenAlex counts PICO Portal stores.
When was Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer published?
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer has 2019 year in the PICO Portal index.
What is the open-access status of Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer?
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer has closed oa status in the PICO Portal index.
What is the DOI of Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer?
The DOI for Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer is on the source record.
What is the PMID of Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer?
The PMID for Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer is on the source record.
What is the OpenAlex record for Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer?
The OpenAlex for Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer is on the source record.